McDermott Advises Owkin on a Multi-Year Clinical Data Science Strategic Collaboration with Bristol Myers Squibb
McDermott Will & Emery has advised French American startup Owkin, which develops artificial intelligence solutions for medical research, on a multi-year strategic collaboration agreement with US laboratory Bristol Myers Squibb (BMS).
The agreement aims to apply Owkin’s artificial intelligence (AI) capabilities to the design of potentially more accurate and efficient clinical trials for Bristol Myers Squibb. The collaboration will initially focus on cardiovascular disease, with the potential to expand to projects in other therapeutic areas.
This collaboration could prove transformative for patient outcomes and scientific progress, making machine learning solutions an integral part of the clinical trial process.
Owkin will use the equity investment to support its ambitious data generation strategy across multiple therapeutic areas, with a focus on rich, multimodal biological data, including the most advanced single-cell spatial omics technologies.
The McDermott team that advised Owkin included:
Emmanuelle Trombe and Anne-France Moreau, partners, on the corporate and health law aspects
Lorraine Maisnier-Boché, associate, on IT and personal data aspects
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.